RS-67,506
| RS-67,506 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
RS-67,506 is a pharmacological compound that acts as a selective 5-HT4 receptor agonist. It has been studied for its potential effects on gastrointestinal motility and cognitive function.
Pharmacology[edit]
RS-67,506 is known for its high affinity and selectivity for the 5-HT4 receptor, a subtype of the serotonin receptor family. The activation of 5-HT4 receptors is associated with increased acetylcholine release in the central nervous system, which can enhance cognitive processes such as learning and memory.
Mechanism of Action[edit]
RS-67,506 binds to the 5-HT4 receptor, which is a G protein-coupled receptor (GPCR). Upon binding, it activates the receptor, leading to the stimulation of adenylate cyclase and an increase in cyclic AMP (cAMP) levels. This cascade results in enhanced neurotransmitter release, particularly acetylcholine, which is crucial for cognitive function and gastrointestinal motility.
Therapeutic Potential[edit]
The compound has been investigated for its potential use in treating conditions such as irritable bowel syndrome (IBS) and Alzheimer's disease. Its ability to enhance gastrointestinal motility makes it a candidate for treating disorders characterized by reduced motility, while its cognitive-enhancing effects suggest potential benefits in neurodegenerative diseases.
Research and Development[edit]
RS-67,506 has been the subject of various preclinical studies. These studies have demonstrated its efficacy in enhancing memory and learning in animal models. However, further research is needed to fully understand its safety profile and therapeutic potential in humans.
Safety and Side Effects[edit]
As with many pharmacological agents, the safety and side effect profile of RS-67,506 is an important consideration. Common side effects observed in preclinical studies include gastrointestinal disturbances and potential cardiovascular effects due to its action on serotonin receptors.
Also see[edit]
- 5-HT4 receptor
- Serotonin receptor
- Gastrointestinal motility
- Cognitive enhancement
- Alzheimer's disease
| Receptor agonists | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Serotonin |
|---|
|
|
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
